AbbVie
ABBV
1,639 hedge funds and large institutions have $62.5B invested in AbbVie in 2016 Q1 according to their latest regulatory filings, with 109 funds opening new positions, 727 increasing their positions, 603 reducing their positions, and 85 closing their positions.
28% more first-time investments, than exits
New positions opened: 109 | Existing positions closed: 85
21% more repeat investments, than reductions
Existing positions increased: 727 | Existing positions reduced: 603
1.93% more ownership
Funds ownership: 68.01% → 69.94% (+1.9%)
3% more call options, than puts
Call options by funds: $651M | Put options by funds: $632M
0% more funds holding
Funds holding: 1,636 → 1,639 (+3)
5% less capital invested
Capital invested by funds: $65.6B → $62.5B (-$3.06B)
16% less funds holding in top 10
Funds holding in top 10: 96 → 81 (-15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal London Asset Management
United Kingdom
|
+$1.24B |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$620M |
| 3 |
VOYA Investment Management
Atlanta,
Georgia
|
+$297M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$193M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$193M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.01B |
| 2 |
State Street
Boston,
Massachusetts
|
-$116M |
| 3 |
EIP
Epoch Investment Partners
New York
|
-$106M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$104M |
| 5 |
Bank of New York Mellon
New York
|
-$101M |
ABBV Hedge Fund Activity: Q1 2016 in Review
1,639 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q1 2016, worth a combined $62.5B — down 4.7% from $65.6B a quarter earlier.
Buyers outnumbered sellers: 109 funds opened new ABBV positions and 85 closed out — a net gain of 24 holders — while 727 added to existing stakes and 603 trimmed.
The largest buyer was Royal London Asset Management, adding an estimated $1.24B. The largest seller was Fidelity Investments, cutting an estimated $1.01B.
- 1,639 institutional investors held AbbVie (ABBV) as of Q1 2016, up from 1,636 in Q4 2015.
- Funds reported $62.5B of AbbVie stock for Q1 2016, down 4.7% quarter-over-quarter.
- 109 funds opened new AbbVie positions in Q1 2016 and 85 closed out, a net change of +24 holders.
- The largest AbbVie buyer in Q1 2016 was Royal London Asset Management, an estimated $1.24B added.
- The largest AbbVie seller in Q1 2016 was Fidelity Investments, an estimated $1.01B sold.
Based on aggregated 13F filings for Q1 2016.